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To evaluate determinants of elevated plasma atrial natri- 
uretic factor levels in patients with hypertension, immuno- 
reactive plasma atrial natriuretic factor in 54 normal 
subjects and 40 untreated hypertensive patients was com- 
pared with echocardiographic measurements of cardiac 
size, function and systemic hemodynamics. In normal sub- 
jects, plasma atrial natriuretic factor was related to age, 
systolic blood pressure and left atrial and ventricular 
chamber sizes, but only age and ventricular size were 
independent predictors. In untreated hypertensive patients, 
atrial natriuretic factor was directly related to age, atrial 
size, systolic pressure, peripheral resistance and ventricu- 
lar systolic performance; age, atrial size and peripheral 
resistance were independent predictors. Eight patients with 
elevated atrial natriuretic factor values (>25 fmollml) were 
significantly (p < 0.01) older and had greater atrial and 
ventricular size and higher systolic pressure and function 
than normal subjects or patients with normal natriuretic 
factor levels. Plasma atrial natriuretic factor was inversely 
related to peak diastolic filling rate in normal subjects (r = 
-0.59; p < O.OOl), whereas it was positively related to the 
proportional contribution of atrial systole to lefl ventricular 
filling in hypertensive patients (r = 0.77; p < 0.001). 
These findings suggest that in normal subjects, impair- 
ment of ventricular relaxation with age may contribute to 
atrial natriuretic factor secretion by increasing left atrial 
aflerload; the correlation with left ventricular size may 
reflect physiologic fluctuations in plasma volume. In pa- 
tients with uncomplicated hypertension, left atrial enlarge- 
ment and consequent stronger atrial contraction contrib- 
uted to increased atrial natriuretic factor release, whereas 
no independent relation existed with left ventricular hyper- 
trophy or systolic function. Because ventricular relaxation 
was normal and ventricular size and systolic performance 
were increased in hypertensive patients with high atrial 
natriuretic factor levels, the observed increase in left atrial 
size and atrial contribution to ventricular filling might 
reflect a primary increase in venous return in this subset of 
hypertensive patients. 
(J Am Co11 Cardiol1989;14:715-24) 
Atrial natriuretic factor is secreted in response to stimuli that 
induce atria1 wall stretch (l-7) or increase the frequency of 
atrial contraction (8.9). The natriuretic and vasorelaxant prop- 
erties of the peptide, as well as its ability to inhibit the 
renin-angiotensin-aldosterone axis (IO), suggest that atrial 
natriuretic factor may be involved in blood pressure regula- 
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tion. This possibility has been supported by the finding that 
plasma atrial natriuretic factor levels are higher on average in 
patients with essential hypertension than in normotensive 
subjects. This difference has been related to blood pressure 
level (I I-13). age (12,14) and electrocardiographic (ECG) 
signs of left ventricular hypertrophy (13,14). Although the 
atria are the only established source of circulating atrial 
natriuretic factor, experimental and limited clinical observa- 
tions (15-21) suggest that atrial natriuretic factor can be 
synthesized in hypertrophied ventricular myocardium and 
that increased plasma levels of it might be correlated with left 
ventricular hypertrophy or failure. These lindings suggest that 
left ventricular hypertrophy as well as systolic or diastolic 
ventricular dysfunction, or both, could be responsible, either 
directly or by inducing atrial enlargement, for increased 
plasma atria1 natriuretic factor levels in hypertension. 
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Table 1. Characteristics of Normotensive and 
Hypertensive Groups 
Variable 
Normotenwe 
Subjects 
(n = 54) 
Hypertensive 
Patients 
(n = 40) 
Age (yr) 
Gender (male/female) 
Race (black/white) 
Systolic blood pressure (mm Hg) 
Diastolic blood pressure (mm Hg) 
51 k II 56 + II 
38116 22ilR 
20133 I/39’ 
129 + IO 154 + 21* 
78 ? 7 96 2 II” 
*p < 0.01 compared wth normotensive subjects. 
Accordingly, the present study was undertaken to exam- 
ine the relative strength of association between plasma atrial 
natriuretic factor levels and concurrent measures of cardiac 
geometry, load and function in normal Fubjects and patients 
with uncomplicated essential hypertension. 
Methods 
Study subjects. The study was performed on 40 patients 
with untreated hypertension and 54 normotensive subjects 
under a protocol approved in 1985 by the Committee on 
Human Rights in Research of the Cornell University Medical 
College. Patients followed up in the New York Hospital 
Hypertension Center for high blood pressure were prospec- 
tively enrolled if they met the following criteria: borderline 
to moderate essential hypertension. off treatment and un- 
complicated by cardiac or renal failure; no history, symp- 
toms or ECG signs of coronary artery disease; absence of 
myocardial, pericardial or valvular disease, except for 
asymptomatic mitral valve prolapse without mitral regurgi- 
tation (one patient); normal sinus rhythm without conduc- 
tion or rhythm disorder and absence of diabetes or other 
systemic diseases. Normotensive subjects were drawn from 
a large group of employed adults that has been previously 
described in part (22). 
Of 136 subjects originally enrolled, 42 were excluded 
because of either poor quality of echocardiographic images 
(24 subjects), lack of simultaneous blood pressure measure- 
ments (10 subjects), Doppler echocardiographic evidence of 
mild aortic regurgitation (3 subjects), heart rate > 120 beatsi 
min (1 subject), hemolysis of atrial natriuretic factor blood 
sample (2 subjects) or age younger than that of any hyper- 
tensive patient (2 normal subjects). 
All patients with hypertension were untreated at the time 
of the study, 25 having never been treated and 15 having not 
received antihypertensive therapy for ~3 weeks. Character- 
istics of normotensive and hypertensive subjects are pre- 
sented in Table 1. 
Echocardiography. M-mode and two-dimensional echo- 
cardiography was performed by an experienced sonogra- 
pher, with the subject in the partial left decubitus position, 
using commercially available echocardiographs with 2.25 to 
3.0 MHz transducers. Two-dimensional views were re- 
corded on 0.5 inch (I .27 cm) videotapes and reviewed using 
a Diasonics Cardio Revue Center with frame by frame 
contour digitizing capability for qualitative analysis and to 
assess left ventricular and atria1 dimensions and volumes. 
Two-dimensionally targeted M-mode tracings were recorded 
on stripchart paper at a rate of 50 mm/s and analyzed by a 
sound pen digitizer interfaced to a Digital PDP I l/23 com- 
puter. with appropriate software for study of systolic and 
diastolic function. Echocardiograms were coded and mea- 
sured blindly in random sequence by two readers (A.G. or 
M.J.R. and R.B.D.). Satisfactory technical quality of both 
M-mode and two-dimensional tracings was obtained in all 94 
subjects studied. Forty-five had sufficiently excellent, con- 
tinuous definition of left ventricular endocardial and pericar- 
dial interfaces for several beats to permit continuous digiti- 
zation of septal and posterior wall endocardial contours 
throughout diastole to assess left ventricular filling dynam- 
ics. M-mode measurements were taken at or just below the 
level of the mitral valve tip. Left ventricular internal dimen- 
sions and ventricular septal and posterior wall thicknesses 
were obtained at end-diastole and end-systole as averaged 
values of up to seven cardiac cycles, and morphologic, 
hemodynamic and functional variables were derived. 
Left ventricu/ur mm was calculated according to the 
Penn convention (23,24) and indexed for body surface area. 
Left ventricular fractional shortening was calculated as a 
measure of systolic performance. End-systolic meridional 
wall stress was calculated from echocardiographic measure- 
ments and simultaneous systolic blood pressure recorded by 
a catheterization-validated formula (25). Because ejection 
phase indexes are highly dependent on afterload (26). indi- 
vidual values of fractional shortening were expressed as a 
percent of the fractional shortening expected for any given 
end-systolic stress. according to the regression equation 
derived from the normal subjects. End-systolic stress/ 
end-systolic volume index ratio was calculated as an index of 
ventricular contractile performance. Left ventricular vol- 
umes were estimated from diastolic and systolic dimensions 
using the Teichholz formula (27), and stroke volume and 
cardiac output were derived. Total peripheral resistance was 
calculated as: ([mean blood pressure x 80licardiac output) in 
dynes s cm-‘. Left atrial diameter was measured at end- 
systole from M-mode tracings (28) and indexed for body 
surface area. Left atrial volume index was determined by 
biplane area-length method from orthogonal planes in apical 
four and two chamber views (29). Right atrial volume index 
was estimated by a single plane area-length method from the 
four chamber view. 
Diastolic phase indexes were directly obtained from 
M-mode digitized recordings by an investigator (P.V.) 
blinded to clinical and laboratory findings. Peak filling rate, 
an index of relaxation, was calculated as the maximal 
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Table 2. Age, Blood Pressure and Atria1 Natriuretic Factor Levels in Normotensive and Hypertensive Subjects, Divided by Race and 
Gender and Matched by Age and Systolic Blood Pressure 
Normotensive Subjects Hypertensive Subjects 
White Black Male Female Male Female 
Variable h = 20) (n = 20) (n = 16) (n = 16) (n = 13) (n = 13) 
Age (yr) 52 ? IO 51 ? 9 51 + 9 57 2 8 572 In 57 2 IO 
Systohc blood pressure (mm Hp) 129 + 9 131 + I1 130 + II 129 ? II I50 + 12 149 * I9 
Atria1 natriuretic factor Cfmolimll I4 2 8 12 2 4 13 ? 5 15 ? 8 15 i- 1 24 2 22 
No differences were statistically significant. 
instantaneous velocity of left ventricular internal dimension 
increase during early diastole, normalized for the instanta- 
neous dimension (dD/dT/D) in s-‘. Rapid filling fraction was 
assessed as percent increase in ventricular dimension from 
the minimal dimension to the point where filling rate de- 
creases to 50% of the peak value divided by the entire 
percent increase in left ventricular dimension during dias- 
tole. Filling fraction during atrial contraction was measured 
as change in left ventricular dimension between the begin- 
ning of ECG P and R waves, expressed as percent of the 
total increase in ventricular dimension during diastole. 
Atrial natriuretic factor determination. Blood samples 
were drawn the same day as echocardiography and blood 
pressure measurement, in most subjects at the end of the 
echocardiographic study, while they were still in the supine 
position. Venous blood samples were collected and stored 
on ice in EDTA Vacutainers (Becton, Dickinson & Co., 
Rutherford, New Jersey) after subjects had been supine for 
20 to 30 min. Plasma atria1 natriuretic factor was measured 
after extraction on Cl8 Sep-Pak cartridges (Waters Associ- 
ates) by a radioimmunoassay (30) that employed antiserum 
raised against human atrial natriuretic factor 99-126 and the 
same peptide as standard (Peninsula Laboratories, Inc.) and 
tracer (Amersham Ltd.). The assay was performed as pre- 
viously described (301, except that bound and free peptides 
were separated using second antibody coupled to a solid- 
phase support (Immunobeads, Bio-Rad Laboratories). 
Other determinations. Hematocrit, serum creatinine 
level, plasma renin activity (31) and 24 h urinary excretion of 
sodium and aldosterone (32) were measured within 3 days of 
natriuretic factor determination without change in treatment. 
Statistical methods. Data were analysed by CLINFO 
statistical software (33) of the Cornell Medical College 
Clinical Research Center. Measurements are expressed as 
mean values, with the standard deviation as the index of 
dispersion. Normality of distribution was tested by the 
Wilk-Shapiro method. Statistical differences among matched 
groups were tested by paired sample f-test or nonparametric 
Wilcoxon paired sample test. Differences among three or 
more groups were tested by one way ANOVA, followed by 
Tukey’s multiple comparison test for unequal sample size 
(34). The relation between variables was assessed with use 
of linear regression analysis and Pearson’s correlation coef- 
ficient; alternatively, Spearman’s rank correlation coefficient 
was used when variables were not normally distributed. 
Multiple stepwise regression analysis was used to test the 
interrelation among atria1 natriuretic factor and several in- 
dependent variables. 
Results 
Subject characteristics (Table 1). There was no statistical 
difference in age between normotensive and untreated 
hypertensive subjects. Systolic and diastolic blood pressures 
were elevated (p < 0.01 versus normotensive subjects) in 
hypertensive patients. Gender and race were not repre- 
sented in the same proportion in the two groups. Accord- 
ingly, their possible influence on plasma atrial natriuretic 
factor values was tested using groups matched for age and 
blood pressure (Table 2). Plasma natriuretic factor values 
were similar in 20 white and 20 black normotensive subjects, 
and no significant difference was observed between men and 
women among normotensive or hypertensive subjects. 
Atrial natrinretic factor levels, laboratory and cardiac 
findings and systemic bemodynamics (Tables 3 and 4). 
Plasma atrial natriuretic factor was higher in hypertensive 
patients (19.2 ? 15.4 fmollml; p < 0.05) than in normotensive 
subjects (13.1 ? 6.3). Plasma peptide values were more than 
2 SD above the normal mean value (>2S fmoliml) in eight 
hypertensive patients (20%). On average, there were no 
significant differences between normotensive and hyperten- 
sive groups in left ventricular diastolic diameter index, 
end-systolic wall stress, fractional shortening, end-systolic 
stress/end-systolic volume index ratio, heart rate, total pe- 
ripheral resistance, serum creatinine, 24 h urinary sodium 
excretion, hematocrit or plasma renin activity. Compared 
with values in normotensive subjects, left atrial diameter 
index, left ventricular mass index, relative wall thickness 
and afterload-independent fractional shortening were all 
significantly increased in hypertensive patients. Cardiac 
index and urinary aldosterone levels were also significantly 
higher in hypertensive patients compared with control pa- 
tients. 
In normal subjects. plasma natriuretic factor was signifi- 
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Table 3. Plasma Atrial Natriuretic Factor and Laboratory Findings in Normotensive and 
Hypertensive Subjects 
Variable 
Normotensive 
Subjects 
(n = 54) 
Hypertenswe 
Patients 
(n = 40) 
Atria1 natriuretic factor (fmolimll 
Serum creatinine (mg/dl) 
Hematocrit (%I 
24 h urinary sodium (mEqi24 h) 
Plasma renin activity i&ml h) per 
Urinary aldosterone (ng/dlt 
13.1 + 6.3 19.2 c 15.4* 
1.10 f 0.2 151) 1.06 + 0.2 (39) 
41.4 5 3.2 ISI) 42.1 2 3.6 (40) 
122 2 65 (47) 118 + 45 (33) 
2.2 2 1.5 (47) 2.3 c 1.9 (36) 
5.9 * 3.5 (34) 10.6 ? 5.7 (17)* 
*p < 0.05 compared with normotensive subjects. Number of cases IS shown in parentheses 
cantly correlated to age, systolic pressure, atrial diameter 
index and ventricular diameter index, but not to diastolic 
pressure or other cardiac or laboratory variables (Table 5). 
Right and left atrial volume index could be measured in 49 of 
the 54 normal subjects, but only the former was significantly 
related to plasma atria1 natriuretic factor level (r = 0.39: p < 
0.004). In hypertensive patients, plasma peptide levels were 
significantly and directly related to age, systolic blood pres- 
sure, left atrial diameter index, total peripheral resistance, 
fractional shortening and afterload-corrected fractional 
shortening, and inversely related to serum creatinine, 
plasma renin activity and hematocrit. In this group of 34 
patients, hematocrit was also significantly related to plasma 
renin activity (r = 0.43; p < 0.01). 
Multiple stepwise regression analysis was performed with 
atria1 natriuretic factor as the dependent variable and age, 
systolic blood pressure, left atrial diameter index, left ven- 
tricular diameter and mass indexes, absolute and afterload- 
corrected fractional shortening and total peripheral resis- 
tance as independent variables (Table 6). Logarithmic 
transformation of natriuretic factor levels was performed in 
the hypertensive group. In normotensive subjects, age and 
left ventricular diameter index were independently related to 
plasma atrial natriuretic factor and were responsible for 28% 
of the total and 72% of the explained variance of peptide 
levels. In hypertensive patients, left atria1 size, peripheral 
resistance and age were independently related to plasma 
atrial natriuretic factor and were responsible for 47% of the 
total and 90% of the explained variance of peptide levels; left 
atrial diameter index alone accounted for 26% of the total 
and 50% of the explained variance. 
Relation of atria1 natriuretic factor to ventricular hyper- 
trophy. The relation of plasma natriuretic factor levels to 
the extent and patterns of left ventricular hypertrophy was 
analyzed, dividing hypertensive patients according to left 
ventricular mass index and relative wall thickness values 
(35). Twenty-four patients had a normal ventricular mass 
index (within 2 SD of the mean value obtained in 221 normal 
subjects), 6 had concentric hypertrophy (ventricular mass 
index and relative wall thickness >2 SD above the normal 
mean value) and IO had eccentric hypertrophy (increased 
ventricular mass, but normal relative wall thickness). In 
these three groups, plasma natriuretic factor was 18.2 + 
18.3, 22.7 2 12.2 and 19.6 * 9.1 fmoliml. respectively. and 
no significant difference was found between normotensive 
and hypertensive groups (Fig. I). 
Table 4. Hemodynamic and Echocardiographic Findings in Normotensive and 
Hypertensive Subjects 
Normotensive 
Subjects 
Variable (n = 54) 
Left ventricular Internal diameter index at end-diastole (cm!m’l 2.6 ? 0.3 
Left atria1 diameter index (cm/m’) 1.7 A 0.2 
Left ventricular mass index (Penn convention) (g/m’) 78 c 20 
Relative wall thickness at end-diastole 0.34 ? 0.04 
End-systolic meridional wall stress (IO’ dynes/cm’) 66? I7 
Fractional shortening (%I 37 ? 6 
Afterload-corrected fractional shortening (5% of predicted) 100 * 9 
End-systolic stress/end-systolic volume index ratio (IO dynes/cm’) 3.3 ? 0.7 
Heart rate (beatsimin) 67 = II 
Cardiac index (litersimin per m’) 2.7 IO.7 
Total peripheral resistance ldyncswm~‘) 1.576 -c 427 
*p < 0.05 compared with normotensive subjects: +p CC 0.01 versus control subjects. 
Hypertensive 
Patients 
In = 40) 
2.7 + 0.3 
1.9 -t 0.3* 
107 ? 24t 
0.40 t 0.06t 
68 z 21 
39 I 7 
105 * 9* 
3.4 2 0.6 
72 + 13 
3.2 ? 0.W 
1,613 ? 374 
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Tsbk 5. Univariatc Correlates of Plasma Atrial Natriuretic Factor Level in Normotensire and Hypertensive Groups 
Vanabk 
Normorensive Sub!ects Hypertensive Patient5 
In = Sal ul = 401 
f P IS P 
AljC 
Sysrolii blood pressure 
Lcfi ventricular mtemal diameter index at enddiastde 
LeA atrtal diameter index 
Left ventncular mass mdex 
Rebtivc wall thickness at enddiastok 
Total peripheral rcsistancc 
Cardiac index 
Fractional shorteninp 
Afterload-corrected fracttonal shortening 
End-systolic stress 
Heart rate 
Serum creatmine 
14 h urinary sodium 
Plasma renin activity 
Urinary aldostcrone 
Hematocnt 
0.43 ~O.OUl 0.52 
0.33 co Ill n.33 
0.37 <0.005 0.25 
040 <O.OO! 0.53 
-0 0: NS 0.11 
-0.10 NS 0.10 
UUY NS 0.39 
0 I? NS ~0.06 
0.13 NS 0.3: 
0.22 NS 0.41 
-0 03 NS -0.16 
-0.07 NS -0.29 
-0.20 ss (51) -0.38 
-o.OY NS (471 -0.30 
-0.IR NS (471 -0.40 
-0.20 NS 134) O.Oi 
-0.X NS (511 -0.59 
<O.UUl 
<0.05 
NS 
<O.OUl 
NS 
NS 
co.02 
NS 
co.05 
<O.Ol 
NS 
NS 
co.05 134) 
NS 03) 
<o.n5 136) 
NS 117) 
COUOI t3iI 
NS = no1 stgnificanl: p = probabilify: r = Pearson comlation cocffictcnt: rs = Spearman corrclatton co&tent. Number of cases ts shown tn parcnthescr. 
Patients with abnormal plasma natriuretic factor values 
025 fmoliml~ were equally distributed among the three 
groups with dithering degrees and patterns of ventricular 
hypertrophy (Fig. 1). In contrast. the eight patients with an 
elevated level of natriuretic factor had significantly higher 
(p < 0.01) systolic pressure, age and left ventricular and 
atrial chamber sizes than normal subjects or hypertensive 
patients with normal peptide levels, whereas left ventricular 
mas5 index was equally elevated in both hypertensive sub- 
groups (Fig. 2). Only 3 of 40 patients had a heart rate >85 
beats/min. none of whom had abnormal levels of plasma 
atrial nali-iuretic factor. 
Left ventrkular systolic performance. Systolic ventricular 
performance as evaluated by fractional shortening and end- 
systolic stress/volume index ratio was not significantly dif- 
ferent between subgroups with normal or increased natri- 
uretic factor levels (39 + 7 and 40 +. 8%. and 3.4 + 0.9 and 
3.6 I 0.6 IO’ dynej/cm3. respectively). When fractional 
shortening was plotted against end-systolic stress. hyperten- 
sive patients with normal plasma natriuretic factor fell within 
the 95% confidence limits of the relation for normal subjects, 
whereas patients with increased plasma peptide levels ex- 
hibited a trend toward high fractional shortening for any 
given level of stress (Fig. 3). Fractional shortening as a 
Table 6. Stepwise Multiple Regression Analysis in Normotensive and Hypertensive Groups 
Grow 
Normotensive 
group In = 54) 
Hypertenstvc 
group In = 40) 
All vartables 
Main vanabks 
Ase 
LVIDI, 
All vanables 
Main variable5 
LADI 
TPR 
A@ 
R 
0.62 
RZ AR? 
0.39 - 
0.19 
0.09 
0.2 0 S! 
0.26 
0 I5 
0.06 
p value 
<:0.0002 
<0.003 
<:0.01 
<0.OOO1 
<o.oo‘l 
<ourI 
CO.04 
Dependent variabk: atrial natrittrctic factor in normotensive group. and logarithm of atrial natriurctic factor in 
hypertensive group. Independent vartables tnclnded in the stcpwice regression model. age. fractional chottening. 
fractional shortening corrected for afterload. left atnat diameter mdex (LADIt. left ventricular internal dtastolic 
diameter index tLVIDI,J. left ventriculat mass Index. systolic blood prewtre. toral peripheral rcs~starme (TPR) p r 
probability; R = multiple correlation coefticicnt: K’ = coefictent of dctermmatiat: 1 R’ = amount of vanance tR‘) 
explained by any main variable. 
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subjects Hypertensive patients 
Figure 1. Individual data and mean values for plasma atrial natri- 
uretic factor (ANF) concentration in normal subjects and hyperten- 
sive patients without left ventricular hypertrophy (No LVH) and 
with concentric or eccentric hypertrophy (Cont. and Etc. LVH, 
respectively). The dashed line represents the upper limit for normal 
plasma atrial natriuretic factor values in our laboratory (25 fmol/ml). 
percent of that predicted for end-systolic stress was signifi- 
cantly higher (p < 0.05) in patients with an increased level of 
plasma natriuretic factor (117 -+ 15%) than in normal sub- 
Figure 2. Percent differences from normal subjects (baseline) in 
hypertensive patients with normal (empty bars; n = 45) and abnor- 
mal (dotted bars; n = 16) plasma atrial natriuretic factor (ANF) 
values. LADI = left atrial diameter index; LVIDI, = left ventricular 
internal diameter index at end-diastole; LVMI = left ventricular 
mass index; SBP = systolic blood pressure; t = p < 0.01 versus 
normal subjects; * = p < 0.01 between hypertensive subgroups with 
normal and abnormal plasma atrial natriuretic factor levels. 
OANF525 
0 ANF725 
40t ““’ 
r--x- 
+ 
AGE SBP 
0 
LVMI LADI LVIDId 
40 80 120 160 
ESS (103dynes/cm2) 
Figure 3. Mean values of end-systolic meridional wall stress (ESS) 
and fractional shortening (FS) from hypertensive patients with 
normal (open triangle) and high (closed triangle) plasma atrial natri- 
uretic factor (ANF) level are plotted on the stress-shortening 
relation obtained in normal subjects; the dotted lines define the 95% 
confidence limits for the normal relation. End-systolic stress is 
expressed in logarithmic scale. The group with high plasma peptide 
levels lies above the upper confidence limit for normal subjects. 
jects (100 * 9%) or in hypertensive patients with a normal 
peptide level (105 ? 10%). 
Left ventricular diastolic performance. Peak filling rate 
and rapid filling fraction were not significantly different in 21 
untreated hypertensive patients (2.9 ? 0.9 s-’ and 63%, 
respectively) compared with 25 normal subjects (3.3 ? 0.6 
S -’ and 64%) whereas filling fraction attributable to atria1 
contraction was significantly higher (p < 0.05) in hyperten- 
sive patients (27 2 I I%) than in normal subjects (19 2 6%). 
There was no significant correlation between rapid filling 
fraction and atria1 natriuretic factor in either normotensive 
(r = 0.11) or untreated hypertensive subjects (r = 0.09). Peak 
filling rate was inversely related to plasma atria1 natriuretic 
factor in normal subjects (r = -0.59; p < 0.001) (Fig. 4) but 
not in the hypertensive patients (r = 0.10). Peak filling rate 
also correlated significantly with age in the normotensive 
group (r = -0.40; p < 0.05) but not in the hypertensive 
group. In contrast, the atria1 contribution to ventricular 
filling exhibited a close relation to plasma peptide levels in 
the hypertensive patients (r = 0.60 for linear and r = 0.77 for 
second degree polynomial regression; p < 0.01 and p < 
0.001, respectively) (Fig. 5), but not in normal subjects (r = 
0.111. 
Figure 4. Inverse linear relation between left ventricular peak filling 
rate (PKFR) and plasma atrial natriuretic factor (ANF) values in 24 
normal subjects. 
01 c 
2.2 2.6 3.0 3.4 3.8 4.2 4.6 5.0 
PKFR k.ec-‘I 
JACC Vol. 14, No. 3 CANAU ET AL. 721 
September 1989.715-24 ATRIAL NATRIURETIC FACTOR IN HYPERTENSION 
Figure 5. Relation between left ventricular killing fraction due to 
atrial contraction (ACF) and plasma atrial natriuretic factor (ANF) 
values in 21 untreated hypertensive patients. The curve becomes 
steeper when the contribution of atrial contraction to ventricular 
filling exceeds 30%. 
Discussion 
Atrial natriuretic factor in hypertension. Atrial natriuretic 
factor can be abnormally elevated in a variety of cardiovas- 
cular disorders, especially when complicated by long-term 
volume overload or congestive heart failure (3.30,3638). 
The present study showed that circulating immunoreactive 
atria1 natriuretic factor is, on average. significantly increased 
in hypertensive patients, consistent with previous reports 
(11-14). We found abnormally high plasma peptide values 
(>25 fmol/ml, upper normal limit in our laboratory) in 20% of 
the patients. 
Although race and gender differed among groups, our 
findings did not appear to be influenced by these factors. In 
fact, plasma atria1 natriuretic factor levels were similar in 
black and white as well as in male and female subjects when 
groups matched for age and systolic blood pressure were 
compared (Table 2). 
From a theoretic point of view, hypertension might cause 
elevation of plasma atria1 natriuretic factor in several ways. 
When left ventricular hypertrophy is present, an increase in 
left ventricular end-diastolic pressure and, consequently, left 
atria1 pressure and wall tension could result from reduced 
ventricular relaxation or compliance or from impaired ven- 
tricular systolic function. In contrast, left atrial enlargement 
may also occur without evidence of ventricular hypertrophy 
(39). possibly reflecting early left ventricular diastolic dys- 
function (40) or greater central blood volume and venous 
return to the left side of the heart (41). Finally, although an 
atrial origin of circulating atrial natriuretic factor has been 
unequivocally demonstrated, some experimental observa- 
tions (l5-19,21) suggest that ventricular myocardium might 
also synthesize the peptide in the setting of induced hemo- 
dynamic overload or ventricular dysfunction; however, as 
yet, there has been no direct demonstration of ventricular 
secretion of natriuretic factor in such conditions. In experi- 
mentally induced hypertension in rats, Garcia et al. (20) 
observed a strong correlation between circulating atrial 
natriuretic factor levels and cardiac weight, suggesting a role 
of myocardial hypertrophy in increasing plasma peptide. In 
human hypertension, some researchers (13,141 have ob- 
served that levels of natriuretic factor are related to ECG 
signs of left ventricular hypertrophy. Accordingly, we tested 
the relation of plasma atrial natriuretic factor to left ventric- 
ular mass and systolic and diastolic function. 
Factors related to atrial natriuretic factor levels in normal 
subjects. Age, left ventricular diastolic dimension. systolic 
blood pressure and left atrial dimension correlated signifi- 
cantly with natriuretic factor levels in normotensive sub- 
jects, but only age and ventricular dimension were indepen- 
dent predictors of plasma levels in multivariate analyses. 
The correlation between atria1 natriuretic factor and age in 
normal subjects, also observed by other investigators 
(12,14,42,43), could reflect age-dependent impairment of 
renal ability to excrete sodium. However, renal function was 
normal in our normal subjects and neither plasma natriuretic 
factor nor age was related to serum creatinine or 24 h sodium 
excretion. Alternatively, aging might result in left atrial 
distension due to an age-related increase in blood pressure or 
impairment of left ventricular diastolic relaxation, or both 
(44). Consistent with this interpretation, both left atrial 
dimension and systolic blood pressure were significantly 
related to atrial natriuretic factor in univariate analyses 
(Table 5). but in multivariate analyses. these correlations 
disappeared when age was entered into the model. In addi- 
tion, plasma peptide levels were inversely related to peak 
left ventricular filling rate (Fig. 4), which in turn was related 
to age. These findings suggest that atria1 natriuretic factor 
release in normal subjects is strongly influenced by age- 
related changes in atrial afterload. In addition, an influence 
of physiologic fluctuations in plasma volume or venous 
return is suggested by the independent relation observed 
between plasma peptide levels and left ventricular diastolic 
chamber size. 
Factors related to atria1 natriuretic factor levels in hyper- 
tensive patients. In hypertensive patients, multivariate anal- 
ysis showed that left atria1 dimension. age, total peripheral 
resistance and systolic blood pressure were independent 
determinants of plasma atrial natriuretic factor values (Table 
6). These data provide strong evidence that left atrial en- 
largement plays a major role in the increased natriuretic 
factor levels observed in patients with hypertension. Al- 
though this finding has not been previously demonstrated in 
the clinical setting, it is not surprising because atrial stretch 
appears to be the most important stimulus for natriuretic 
factor secretion under physiologic conditions (7). Similar to 
previous reports (II-l4), we found that atrial natriuretic 
factor levels were positively related to blood pressure in 
hypertensive patients. Because total peripheral resistance 
also correlated with natriuretic factor, this suggests that 
peptide secretion increases in parallel with the severity of 
arterial vasoconstriction. Although age was an independent 
determinant of atria1 natriuretic factor in hypertensive pa- 
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tients, as in control subjects, its contribution was less than 
that of left atrial size and total peripheral resistance or blood 
pressure, reflecting the superimposition of additional fac- 
tors. 
Role of decreased plasma renin activity. Serum creati- 
nine and 24 h urinary sodium excretion were similar in 
hypertensive patients and normal subjects, suggesting that 
differences in kidney function or sodium intake do not 
account for the observed differences in plasma peptide 
values. However, plasma atrial natriuretic factor was in- 
versely related to plasma renin activity among untreated 
hypertensive patients (Table 5). Although the ability of atrial 
natriuretic factor to inhibit renin secretion (30) might con- 
tribute to this relation, suppressed plasma renin levels can 
also reflect expansion of extracellular and plasma volume. 
The latter interpretation is reinforced by our finding of an 
inverse relation between plasma atrial natriuretic factor and 
hematocrit (Table 5). At the same time, hematocrit was 
directly related to plasma renin activity. Taken together, 
these observations suggest that plasma volume expansion, 
as reflected by lower plasma renin activity and lower hemat- 
ocrit, might be responsible for increased atrial size and atrial 
natriuretic factor secretion in some hypertensive patients. 
When hypertensive patients with increased plasma natri- 
uretic factor were analyzed as u distinct subgroup (Fig. 2), 
they were found to be significantly older and had higher 
systolic blood pressure and left atria1 dimension than did 
normal subjects and hypertensive patients with normal 
plasma peptide levels. Left ventricular diastolic dimension 
and fractional shortening corrected for afterload were both 
increased in this subgroup, whereas ventricular mass and 
relative wall thickness were similar to those in hypertensive 
patients with normal atrial natriuretic factor. 
Relation to plasma atrial natriuretic factor to left ventric- 
ular hypertrophy and function. Our data do not support a 
direct link between left ventricular hypertrophy and in- 
creased plasma natriuretic factor levels in patients with 
hypertension. There was no relation between plasma peptide 
levels and indexes of ventricular hypertrophy (Table 5). 
When patients were classified according to the pattern of 
hypertrophy (Fig. I), there was a wide overlap in atrial 
natriuretic factor levels, without statistically significant dif- 
ferences among normotensive and hypertensive patients 
with normal ventricular mass or with concentric or eccentric 
hypertrophy. Others have reported that plasma natriuretic 
factor is higher in patients with ECG signs of left ventricular 
hypertrophy (13,14) or increased cardiothoracic ratio (14). 
However, these criteria of left ventricular hypertrophy are 
less sensitive than the echocardiographic indexes used in the 
present study (45). suggesting that more severe forms of 
ventricular hypertrophy might have been identified in previ- 
ous analyses. This would also appear to be true of the 
patients reported by Wambach et al. (46), in whom systolic 
blood pressure at rest after 4 days of hospitalization (which 
averaged 15 mm Hg higher than the relatively basal levels in 
the present study) was found to be significantly related to left 
ventricular mass, which ranged up to 500 g. In addition, two 
previous studies (13,14) included patients with renal involve- 
ment, which may reflect more severe or long-standing hy- 
pertension and which could contribute independently to 
increased atrial natriuretic factor levels (47). Although we 
cannot completely exclude that severe left ventricular hy- 
pertrophy might be responsible for increased atria1 natri- 
uretic factor levels, our data do not provide evidence to 
support this mechanism among less severely affected hyper- 
tensive patients. 
Role qf left ventricular diastolic dysfunction and left 
atriul distension. Evidence does exist, however, that in- 
creases in left ventricular mass within the normal range may 
modify ventricular diastolic properties (40) and could 
thereby indirectly influence atrial natriuretic factor release. 
When left ventricular chamber stiffness increases as a con- 
sequence of the hypertrophic process, ventricular diastolic 
pressure as well as atrial pressure tend to increase (48). Our 
data showed a close relation in hypertensive patients be- 
tween atrial natriuretic factor and the fraction of ventricular 
filling that occurred during atria1 contraction (Fig. 5). Even 
though the plot is linear and nearly flat at normal or mildly 
increased values of atrial contribution to ventricular filling, 
the slope becomes steeper when atrial contraction contrib- 
utes >30% of the total ventricular filling. This suggests that 
a critical level of atrial distension (or contraction) has to be 
achieved to increase peptide secretion. The increased con- 
tribution of atrial contraction to ventricular filling reflects a 
more powerful atrial systole, consistent with an atrial Star- 
ling mechanism due to the observed left atrial chamber 
enlargement. Two mechanisms could be responsible for 
distension and stronger contraction of atria1 wall: increased 
left ventricular diastolic and, hence, left atrial pressure as a 
result of reduced ventricular distensibility. or increased 
venous blood return to the left side of the heart. Although we 
cannot exclude some increase in ventricular chamber stiff- 
ness. the normality of ventricular relaxation in our patients 
with high levels of atria1 natriuretic factor suggests that 
severe impairment of diastolic properties was not present in 
these patients. Indirect support for the hypothesis of in- 
creased venous return is provided by the association with 
increased left ventricular diastolic dimension and relatively 
high fractional shortening, both of which reflect high left 
ventricular preload. An increase in venous return has been 
described in subsets of hypertensive patients, particularly 
those with low plasma renin, and could be related to blood 
volume expansion or high cardiopulmonary blood volume 
due to decreased peripheral venous distensibility (41,49,50). 
Further research is needed to clarify the relation between 
plasma and blood volume and atrial natriuretic factor levels 
in hypertensive patients. 
Role of leji ventricular systolic function. Plasma atrial 
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natriuretic factor may reach very high levels when left 
ventricular systolic function is dramatically reduced, as in 
congestive heart failure (30,3638). Likewise an inverse 
relation between plasma natriuretic peptide levels during 
exercise and fractional shortening before exercise has been 
observed in hypertensive patients (51). Accordingly, we also 
evaluated systolic function in relation to plasma natriuretic 
factor levels. In the patients with high natriuretic factor 
levels, fractional shortening was normal in absolute terms or 
even supranormal when analyzed in relation to afterload 
(Fig. 3). An increase in myocardial contractility or preload 
might induce the observed shift toward higher values of 
fractional shortening for any given level of end-systolic wall 
stress (52). Because the ratio of end-systolic stress to end- 
systolic volume was normal and left ventricular diastolic 
dimensions were increased in patients with high atrial natri- 
uretic factor levels (Fig. 4). an increase in preload seems to 
be the most appropriate interpretation. 
Conclusions. We found that plasma atrial natriuretic fdc- 
tor levels are related to hemodynamics, left ventricular and 
left atrial chamber size and left ventricular diastolic function 
in both normal and hypertensive subjects. In normal sub- 
jects, correlations of natriuretic peptide levels with ventric- 
ular and atrial dimensions may reflect a postulated role of 
this peptide in offsetting physiologic fluctuations in plasma 
volume. Relative impairment of ventricular relaxation with 
age may also increase left atrial afterload and contribute to 
atria1 enlargement. as suggested by the inverse relation 
between natriuretic factor levels and peak filling rate. In our 
series, plasma atrial natriuretic factor levels were increased 
in approximately 20% of patients with mild uncomplicated 
hypertension who were able to be withdrawn from treatment 
or had never been treated. There was no relation between 
plasma atrial natriuretic factor levels and either left ventric- 
ular hypertrophy or systolic dysfunction, suggesting that 
these factors were not directly involved in increased peptide 
secretion, Left atrial enlargement and stronger atria1 con- 
traction seem to be the most important mechanisms involved 
in increased atrial natriuretic factor release in patients with 
hypertension. The increases in left atrial size and atrial 
contribution to left ventricular filling most likely reflect a 
primary increase in venous return to the left side of the 
heart. 
We thank Katie Pondolfino, RN and Mary Clark. RN for their assistance in 
obtaining specimens, Virginia Burns for preparation of the manuscript and 
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